Alamar Biosciences Inc (ALMR)

Currency in USD
34.61
-0.03(-0.09%)
Real-time Data·
ALMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.4936.10
52 wk Range
18.8538.54
Key Statistics
Prev. Close
34.64
Open
34.93
Day's Range
34.49-36.1
52 wk Range
18.85-38.54
Volume
156.1K
Average Vol. (3m)
321.74K
1-Year Change
-
Book Value / Share
4.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALMR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.40
Downside
-3.50%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Alamar Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 33.40
(-3.50% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy35.00+1.48%32.00MaintainAug 11, 2026
Stifel
Buy32.00-7.22%28.00MaintainAug 11, 2026
Stifel
Buy28.00-18.82%28.00MaintainJun 09, 2026

Alamar Biosciences Inc Earnings Call Summary for Q2/2026

  • Q2 revenue surged 82% YoY to $29.4M; consumables jumped 147% to comprise 53% of sales; gross margin hit record 60%
  • Net loss widened to $13.2M vs $7.0M YoY as operating expenses rose 89%; company posted -$0.22 EPS but remains well-funded with $256.3M cash
  • Management raised FY2026 revenue guidance to $116M-$120M, implying 59% growth; expects Q3 revenue up low single digits sequentially
  • Company targets 100+ instrument placements in 2026 with $400K+ annual pull-through per unit; expanding Fremont manufacturing capacity
  • Shares flat after-hours at $27.99; stock trades near 52-week high but InvestingPro flags valuation concerns at $1.97B market cap
Last Updated: 08/10/2026, 05:32 PM
Read Full Transcript
Alamar Biosciences investor slides for Q2/2026
Alamar Q2 2026 slides
Last Update: Aug 10, 2026
See full investor slides

Earnings

Latest Release
Aug 10, 2026
EPS / Forecast
-0.22 / --
Revenue / Forecast
29.4M / --
EPS Revisions
Last 90 days

ALMR Income Statement

Compare ALMR to Peers and Sector

Metrics to compare
ALMR
Peers
Sector
Relationship
P/E Ratio
−48.8x−1.7x−0.3x
PEG Ratio
-−0.030.00
Price / Book
7.7x0.8x2.6x
Price / LTM Sales
24.1x3.8x3.1x
Upside (Analyst Target)
−1.8%17.4%47.6%
Fair Value Upside
Unlock−10.1%5.6%Unlock

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company’s offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.47M7.89%194.29M
Other Institutional Investors
53.71M77.49%1.91B
Public Companies & Retail Investors
10.13M14.62%360.16M
Total
69.31M100.00%2.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited15.29%10,594,547376,530
Qiming Venture Partners VI, L.P.9.93%6,881,410244,565

People Also Watch

18.95
XE
+3.58%
53.40
ARXS
-0.56%
8.22
POET
-0.67%
135.90
SPCX
+1.42%

FAQ

What Is the Alamar Biosciences (ALMR) Stock Price Today?

The Alamar Biosciences stock price today is 34.61 USD.

What Stock Exchange Does Alamar Biosciences Trade On?

Alamar Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alamar Biosciences?

The stock symbol for Alamar Biosciences is "ALMR."

What Is the Alamar Biosciences Market Cap?

As of today, Alamar Biosciences market cap is 2.40B USD.

What Is Alamar Biosciences's Earnings Per Share (TTM)?

The Alamar Biosciences EPS (TTM) is -2.10.

When Is the Next Alamar Biosciences Earnings Date?

Alamar Biosciences will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is ALMR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alamar Biosciences Stock Split?

Alamar Biosciences has split 0 times.

How Many Employees Does Alamar Biosciences Have?

Alamar Biosciences has 286 employees.

What is the current trading status of Alamar Biosciences (ALMR)?

As of Aug 21, 2026, Alamar Biosciences (ALMR) is trading at a price of 34.61 USD, with a previous close of 34.64 USD. The stock has fluctuated within a day range of 34.49 USD to 36.10 USD, while its 52-week range spans from 18.85 USD to 38.54 USD.

What Is Alamar Biosciences (ALMR) Price Target According to Analysts?

The average 12-month price target for Alamar Biosciences is 33.40 USD, with a high estimate of 35 USD and a low estimate of 31 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -3.50% Downside potential.

What Is the ALMR Premarket Price?

ALMR's last pre-market stock price is 34.99 USD. The pre-market share volume is 680.00, and the stock has decreased by 0.35, or 1.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.